Alendronic Acid

also known as alendronate · alendronate sodium · Fosamax · ALN · MK0217 · Acide alendronique · Acido alendronico · Adrovance · +20 more

Small molecule targets FDPS via inhibition

Developed for: osteoporosis · postmenopausal osteoporosis · HIV infectious disease · bone resorption disease · chronic periodontitis · primary hyperparathyroidism · prostate cancer · spinal cord injury
+30 more
· alveolar periostitis · asthma · avascular necrosis · bone Paget disease · breast cancer · breast neoplasm · cerebral palsy · cervical cancer · chronic renal failure syndrome · corticosteroid-induced osteoporosis · disease related to solid organ transplantation · ischemic disease · metastatic carcinoma in the bone · osteoarthritis, knee · osteogenesis imperfecta · osteomyelitis · osteonecrosis · periodontal disorder · polyostotic fibrous dysplasia · rheumatoid arthritis · aortic valve stenosis · arteriosclerosis disorder · bone disorder · calcinosis · depressive disorder · disease of bone structure · glucocorticoid-induced osteoporosis · impaired renal function disease · NAFLD1 · secondary avascular necrosis
Investigated by: Organon and Co · Merck Sharp & Dohme LLC · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Amgen · Massachusetts General Hospital · National Institute of Allergy and Infectious Diseases (NIAID)
+83 more
· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Taiwan University Hospital · Eli Lilly and Company · Elizabeth Glaser Pediatric AIDS Foundation · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Glaser Pediatric Research Network · GlaxoSmithKline · Medical University of South Carolina · National Heart, Lung, and Blood Institute (NHLBI) · National Institute on Aging (NIA) · Northwestern University · Peking Union Medical College Hospital · Aarhus University Hospital · Ain Shams University · Alberta Heritage Foundation for Medical Research · AstraZeneca · Barwon Health · Boston Children's Hospital · CIHR Canadian HIV Trials Network · CSPC Ouyi Pharmaceutical Co., Ltd. · Children's Hospital Medical Center, Cincinnati · Chinese University of Hong Kong · Ciudad Universitaria, Spain · Columbia University · Dennis Black · Department of Clinical Research and Innovation · Doris Duke Charitable Foundation · Dr. Itay GoorAryeh · Dutch Health Care Insurance Board · EffRx Pharmaceuticals SA · Endo USA Inc., a Keenova Therapeutics Company · FDA Office of Orphan Products Development · Far Eastern Memorial Hospital · Federal University of Minas Gerais · French National Agency for Research on AIDS and Viral Hepatitis · Gilles Boire · Government Dental College and Research Institute, Bangalore · Hartmut Malluche, MD · Health Research, Inc. · Hebrew SeniorLife · Helen Hayes Hospital · Hoffmann-La Roche · Istituto Auxologico Italiano · Kaohsiung Medical University Chung-Ho Memorial Hospital · McGill University Health Centre/Research Institute of the McGill University Health Centre · Merck Frosst Canada Ltd. · Milton S. Hershey Medical Center · Ministry of Science and Higher Education, Poland · Mylan Pharmaceuticals Inc · Nahda University · National Cancer Institute (NCI) · National Cheng-Kung University Hospital · National Institute of Dental and Craniofacial Research (NIDCR) · National Institute of Mental Health (NIMH) · National Institutes of Health (NIH) · National Natural Science Foundation of China · Novartis Pharmaceuticals · Odense University Hospital · Ono Pharma USA Inc · Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre · Paul F Netzel · Pontifícia Universidade Católica de Minas Gerais · Procter and Gamble · Radius Health, Inc. · Second Affiliated Hospital, School of Medicine, Zhejiang University · Shandong New Time Pharmaceutical Co., LTD · Teva Pharmaceuticals USA · UMC Utrecht · Unity Health Toronto · University Hospital, Ghent · University of Alberta · University of California, Davis · University of Chicago · University of North Carolina · all 89 on the full record

Regulatory milestones approvals, filings & regulatory actions · 9 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (7)	US (FDA)	FOSAMAX	—	1997-04-25 – 2005-12-21	fda.gov ↗
Approved	EU (EMA)	Fosavance	—	2005-08-24	europa.eu ↗
Approved	US (FDA)	FOSAMAX	—	1995-09-29	fda.gov ↗

Trials 91 · started per year

today

US approved 1995

EU approved 2005

1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 17 trials
Phase 1	NCT06772792	Apr → Jun 2024	—	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT02781805	Aug 2016 → Dec 2018	breast neoplasm	University of Wisconsin, Madison	Terminated	No outcome recorded
Phase 1	NCT02057263	Apr 2014 → Feb 2016	hepatitis B virus infection	Massachusetts General Hospital	Completed	No outcome recorded
Phase 1	NCT01526278	Oct 2011 → Jul 2012	osteoporosis	Yuyu Pharma, Inc.	Completed	No outcome recorded
Phase 1	NCT00641771	May 2004 → Aug 2005	osteoporosis	Organon and Co	Completed	No outcome recorded
Phase 1	NCT01012934	Jul → Aug 2002	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00835406	Jun → Jul 2000	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT07245381	Dec 2025 → Aug 2026 overdue	cervical cancer	Dr. Itay GoorAryeh	Not yet recruiting	No outcome recorded
Phase 221 trials · 3 missed
Phase 2	NCT07216794	Jul 2026 → Mar 2027 expected	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Recruiting	No outcome recorded
Phase 2	NCT06016634	Mar 2026 → Sep 2027 expected	avascular necrosis, ischemic disease, sickle cell disease	University of California, Davis	Recruiting	No outcome recorded
Phase 2	NCT04708886	Mar 2021 → Jun 2024	osteoporosis, paraplegia, spinal cord injury	Northwestern University	Completed	No outcome recorded
Phase 2	NCT04403698	Nov 2019 → Mar 2022	arthropathy, erosive	University Hospital, Ghent	Completed	Mixed
Phase 2	NCT01968850	Apr 2014 → Mar 2018	HIV infectious disease	Unity Health Toronto	Completed	No outcome recorded
Phase 2	NCT02195895	Apr 2014 → Aug 2016	osteoporosis, spinal cord injury	Northwestern University	Completed	No outcome recorded
Phase 2	NCT01460654	Oct 2011 → May 2014	hypogonadism, osteoporosis	Massachusetts General Hospital	Terminated	No outcome recorded
Phase 2	NCT00921557	Nov 2009 → Jan 2016	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	Mixed
Phase 2	NCT00996801	Nov 2009 → Jun 2011	postmenopausal osteoporosis	Merck Sharp & Dohme LLC	Completed	Missed primary
Phase 2	NCT02168543	Mar 2009 → Jan 2011	chronic periodontitis	Government Dental College and Research Institute, Bangalore	Completed	No outcome recorded
Phase 2	NCT00532337	Oct 2007 → Jul 2010	osteoporosis	Ono Pharma USA Inc	Completed	No outcome recorded
Phase 2	NCT00668941	Sep 2005 → Feb 2016	osteoporosis	Helen Hayes Hospital	Unknown	Missed primary
Phase 2	NCT00259857	Oct 2003 → Mar 2008	osteoporosis	Medical University of South Carolina	Completed	No outcome recorded
Phase 2	NCT00010439	Sep 2000 → Oct 2003	osteoporosis	Medical University of South Carolina	Completed	No outcome recorded
Phase 2	NCT00005005	Oct 1999 → Nov 2007	osteoporosis	Dennis Black	Completed	Missed primary
Phase 2	NCT00000400	Aug 1999 → Apr 2006	osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00019695	Mar 1999 → Mar 2005	metastatic carcinoma in the bone, prostate adenocarcinoma	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 2	NCT00004488	Oct 1998 → Sep 2002	Gaucher disease, osteoporosis	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 2	NCT00001728	Aug 1998 → Aug 2007	polyostotic fibrous dysplasia	National Institute of Dental and Craniofacial Research (NIDCR)	Completed	Mixed
Phase 2	NCT00001720	Mar 1998 → Jun 2003	osteoporosis	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Phase 2	NCT00061256	? → Sep 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 2/35 trials · 1 met primary · 1 missed
Phase 2/3	NCT04169698	Oct 2019 → May 2021	disease related to solid organ transplantation, osteoporosis	Ain Shams University	Completed	Met primary
Phase 2/3	NCT02230332	Jan 2015 → Sep 2016	asthma	Milton S. Hershey Medical Center	Completed	Missed primary
Phase 2/3	NCT00297830	Nov 2005 → Apr 2010	bone resorption disease	Columbia University	Completed	No outcome recorded
Phase 2/3	NCT00277251	Mar 2003 → Jun 2006	corticosteroid-induced osteoporosis	Boston Children's Hospital	Completed	No outcome recorded
Phase 2/3	NCT00209469	Jul 2002 → Feb 2007	osteoporosis	Glaser Pediatric Research Network	Unknown	No outcome recorded
Phase 330 trials · 6 met primary · 1 missed
Phase 3	NCT07435051	May 2026 → Dec 2029 expected	osteomyelitis	Second Affiliated Hospital, School of Medicine, Zhejiang University	Not yet recruiting	No outcome recorded
Phase 3	NCT05602493	Nov 2022 → Oct 2024 overdue	alveolar periostitis	Xeolas Pharmaceuticals Limited	Active not recruiting	No outcome recorded
Phase 3	NCT05305183	May 2022 → May 2023	osteoporosis	Shandong New Time Pharmaceutical Co., LTD	Unknown	No outcome recorded
Phase 3	NCT01657162	Nov 2012 → Oct 2016	postmenopausal osteoporosis	Radius Health, Inc.	Completed	No outcome recorded
Phase 3	NCT01631214	May 2012 → Feb 2017	postmenopausal osteoporosis	Amgen	Completed	Met primary
Phase 3	NCT01437111	Oct 2011 → Dec 2012	osteoporosis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00822029	Feb 2009 → Feb 2011	cerebral palsy, osteoporosis	Department of Clinical Research and Innovation	Terminated	No outcome recorded
Phase 3	NCT00692913	Jun 2008 → Jul 2010	osteoporosis	Organon and Co	Completed	Met primary
Phase 3	NCT00518531	Sep 2007 → Jun 2009	osteoporosis	Amgen	Completed	Met primary
Phase 3	NCT00421343	Feb 2007 → Jun 2008	osteoporosis	Hebrew SeniorLife	Completed	No outcome recorded
Phase 3	NCT00400530	Dec 2005 → ?	osteoporosis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00122356	Sep 2005 → Feb 2013	breast cancer	Barwon Health	Completed	No outcome recorded
Phase 3	NCT00120757	Oct 2004 → Nov 2008	HIV infectious disease, osteoporosis	French National Agency for Research on AIDS and Viral Hepatitis	Completed	Met primary
Phase 3	NCT00092079	Jan → Nov 2004	osteoporosis, vitamin D deficiency	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00092066	Sep 2003 → May 2004	osteoporosis, vitamin D deficiency	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00092027	Mar 2003 → Mar 2004	postmenopausal osteoporosis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00092040	Mar 2003 → Oct 2004	postmenopausal osteoporosis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00346190	Jan 2003 → Apr 2007	osteoporosis	McGill University Health Centre/Research Institute of the McGill University Health Centre	Unknown	No outcome recorded
Phase 3	NCT00092014	Sep 2002 → Apr 2004	postmenopausal osteoporosis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00048841	May 2002 → Dec 2005	hypogonadism, osteoporosis, prostate cancer	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
Phase 3	NCT00177619	May 2002 → Dec 2005	prostate cancer	University of Pittsburgh	Completed	No outcome recorded
Phase 3	NCT00136058	Jan 2002 → Apr 2006	osteoporosis	University of Alberta	Completed	No outcome recorded
Phase 3	NCT00480662	Oct 2001 → Oct 2002	bone Paget disease	Organon and Co	Completed	Missed primary
Phase 3	NCT00480766	Jul 2001 → Aug 2003	osteoporosis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00389740	Apr 2001 → Jan 2003	postmenopausal osteoporosis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00138983	May 2000 → Nov 2003	granulomatosis with polyangiitis, polymyalgia rheumatica, polymyositis, rheumatoid arthritis +1	UMC Utrecht	Completed	Met primary
Phase 3	NCT00000430	Oct 1999 → Sep 2004	osteoporosis	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Terminated	No outcome recorded
Phase 3	NCT00000427	Sep 1999 → Oct 2005	osteoporosis	Massachusetts General Hospital	Completed	Met primary
Phase 3	NCT00398931	Feb 1998 → Oct 2003	postmenopausal osteoporosis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00398606	Apr 1995 → Feb 1998	postmenopausal osteoporosis	Organon and Co	Completed	No outcome recorded

Phase 422 trials · 2 met primary · 1 missed
Phase 4	NCT06864130	Feb 2025 → Mar 2029 expected	postmenopausal osteoporosis	Odense University Hospital	Recruiting	No outcome recorded
Phase 4	NCT06264609	Feb 2024 → Dec 2029 expected	osteoporosis	Paul F Netzel	Enrolling by invitation	No outcome recorded
Phase 4	NCT05764733	Jun 2023 → Jan 2028 expected	bone resorption disease	Wake Forest University Health Sciences	Recruiting	No outcome recorded
Phase 4	NCT05527548	Dec 2022 → Oct 2025	—	Chinese University of Hong Kong	Unknown	No outcome recorded
Phase 4	NCT05091099	Jan 2022 → Nov 2025	osteoporosis	National Taiwan University Hospital	Completed	No outcome recorded
Phase 4	NCT05325515	Oct 2021 → Sep 2022	osteoporosis	Aarhus University Hospital	Completed	No outcome recorded
Phase 4	NCT04739592	Jul 2021 → Jul 2023	osteoarthritis, knee	Peking Union Medical College Hospital	Unknown	No outcome recorded
Phase 4	NCT05387200	Jul 2021 → May 2023	osteoporosis	Yonsei University	Unknown	Met primary
Phase 4	NCT02795546	Jan 2015 → Apr 2016	periodontal disorder	Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre	Completed	No outcome recorded
Phase 4	NCT02470611	Nov 2012 → Nov 2013	bone resorption disease, chronic periodontitis	Federal University of Minas Gerais	Completed	No outcome recorded
Phase 4	NCT01350934	Jun 2011 → Jan 2013	postmenopausal osteoporosis	Organon and Co	Completed	Met primary
Phase 4	NCT02417389	May 2008 → Oct 2011	osteoporosis, primary hyperparathyroidism	Istituto Auxologico Italiano	Completed	No outcome recorded
Phase 4	NCT02303873	Mar 2007 → Jul 2011	osteogenesis imperfecta	Peking Union Medical College Hospital	Completed	No outcome recorded
Phase 4	NCT00299572	Mar → Dec 2006	—	Far Eastern Memorial Hospital	Unknown	No outcome recorded
Phase 4	NCT00261625	Aug 2005 → Oct 2007	end stage renal failure, osteoporosis	National Taiwan University Hospital	Completed	No outcome recorded
Phase 4	NCT00265252	Jun 2005 → Jun 2008	osteonecrosis	Kaohsiung Medical University Chung-Ho Memorial Hospital	Unknown	Missed primary
Phase 4	NCT00327990	Apr 2005 → Dec 2006	osteoporosis	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00079924	Nov 2004 → May 2007	postmenopausal osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT02598440	Mar 2004 → May 2005	postmenopausal osteoporosis	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT01882400	May 2001 → Sep 2007	cystic fibrosis, muscular dystrophy, osteoporosis	Gilles Boire	Completed	No outcome recorded
Phase 4	NCT00006180	Aug 2000 → Jan 2007	major depressive disorder, osteoporosis	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 4	NCT00035971	—	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded

Phase not applicable5 trials · 1 missed
—	NCT02440581	Jul 2015 → Jun 2021	chronic renal failure syndrome	Hartmut Malluche, MD	Completed	Missed primary
—	NCT01889134	Jan 2009 → Jun 2012	primary hyperparathyroidism	Wroclaw Medical University	Completed	No outcome recorded
—	NCT00145977	Jul 2001 → Dec 2009	osteoporosis	University of Chicago	Completed	No outcome recorded
—	NCT00004489	Oct 1998 → Sep 2002	cystic fibrosis, osteoporosis	University of North Carolina	Completed	No outcome recorded
—	NCT00936260	Jan 1998 → Dec 2004	osteoporosis	Ciudad Universitaria, Spain	Completed	No outcome recorded
Comparator or background therapy69 trials
Phase 1	NCT00577850 Comparator	Nov 2002 → Feb 2004	osteoporosis	Warner Chilcott	Completed	No outcome recorded
Phase 1	NCT00983996 Comparator	Jun → Jul 2002	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1/2	NCT04140006 Comparator	Jul 2019 → Jul 2020	—	University of Baghdad	Unknown	No outcome recorded
Phase 2	NCT06973109 Comparator	Jun 2026 → Mar 2027	postmenopausal osteoporosis	University of Pittsburgh	Withdrawn	No outcome recorded
Phase 2	NCT07471880 Comparator	Dec 2024 → Oct 2026 expected	secondary avascular necrosis	ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.	Active not recruiting	No outcome recorded
Phase 2	NCT05397938 Comparator	Jun → Jul 2022	glucocorticoid-induced osteoporosis	Shanghai JMT-Bio Inc.	Unknown	No outcome recorded
Phase 2	NCT03980847 Comparator	Feb 2018 → Mar 2019	bone resorption disease	Islamic Azad University, Sanandaj	Completed	No outcome recorded
Phase 2	NCT03396315 Comparator	Jan 2018 → Jun 2023	osteoporosis	Columbia University	Completed	No outcome recorded
Phase 2	NCT02944799 Comparator	Dec 2015 → Dec 2021	osteoporosis, rheumatoid arthritis	University of Aarhus	Completed	No outcome recorded
Phase 2	NCT02132026 Comparator	Nov 2014 → Nov 2019	aortic valve stenosis	University of Edinburgh	Completed	No outcome recorded
Phase 2	NCT00896532 Comparator	Jun 2009 → Feb 2011	postmenopausal osteoporosis	Amgen	Completed	Met primary
Phase 2	NCT00471237 Comparator	May 2007 → Dec 2008	osteoporosis	GlaxoSmithKline	Terminated	Met primary
Phase 2	NCT00666627 Comparator	Apr 2007 → Sep 2012	postmenopausal osteoporosis	Sheffield Teaching Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 2	NCT00293813 Comparator	May 2006 → Mar 2008	postmenopausal osteoporosis	Amgen	Completed	Met primary
Phase 2	NCT00043186 Comparator	May 2002 → Apr 2007	osteoporosis	Amgen	Completed	Met primary
Phase 2	NCT00005006 Comparator	Sep 1987 → Feb 2003	osteoporosis	Helen Hayes Hospital	Completed	No outcome recorded
Phase 2/3	NCT03040531 Comparator	Jan 2017 → Jun 2018	corticosteroid-induced osteoporosis	University of Messina	Unknown	No outcome recorded
Phase 2/3	NCT03204097 Comparator	Mar 2016 → Feb 2017	chronic periodontitis	Government Dental College and Research Institute, Bangalore	Completed	No outcome recorded
Phase 2/3	NCT02455869 Comparator	Jul 2014 → Mar 2015	chronic periodontitis	Government Dental College and Research Institute, Bangalore	Completed	No outcome recorded
Phase 2/3	NCT02461667 Comparator	Jul 2014 → Mar 2015	chronic periodontitis	Government Dental College and Research Institute, Bangalore	Completed	No outcome recorded
Phase 3	NCT07028320 Comparator	Dec 2021 → Dec 2023	postmenopausal osteoporosis	Shenzhen Salubris Pharmaceuticals Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT03292146 Background	Oct 2017 → Jul 2021	anorexia nervosa, bone resorption disease	Massachusetts General Hospital	Completed	Met primary
Phase 3	NCT04704947 Background	Oct 2017 → Oct 2030 expected	poisoning	Tanta University	Recruiting	No outcome recorded
Phase 3	NCT01552122 Comparator	May 2012 → Feb 2015	postmenopausal osteoporosis	Merck Sharp & Dohme LLC	Withdrawn	No outcome recorded
Phase 3	NCT01512446 Comparator	Feb 2012 → Mar 2013	osteoporosis	Evangelisches Krankenhaus Lutherhaus gGmbH	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00680953 Comparator	May 2008 → Jun 2012	osteoporosis	Daiichi Sankyo	Completed	Met primary
Phase 3	NCT00463268 Comparator	Sep 2007 → Jan 2012	osteoporosis	University Hospital of Mont-Godinne	Completed	No outcome recorded
Phase 3	NCT00404820 Comparator	Oct 2006 → Dec 2008	osteoporosis	Novartis	Completed	No outcome recorded
Phase 3	NCT00377819 Comparator	Sep 2006 → Mar 2008	postmenopausal osteoporosis	Amgen	Completed	Met primary
Phase 3	NCT00330460 Comparator	May 2006 → Nov 2007	osteoporosis	Amgen	Completed	Met primary
Phase 3	NCT00391404 Comparator	May 2006 → Oct 2008	osteoporosis	Chinese University of Hong Kong	Unknown	No outcome recorded
Phase 3	NCT00354302 Background	Apr 2006 → Mar 2011	female breast carcinoma, osteoporosis	NCIC Clinical Trials Group	Completed	No outcome recorded
Phase 3	NCT00236002 Comparator	Jul 2005 → Nov 2007	osteoporosis	Canadian Urology Research Consortium	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00051558 Comparator	Nov 2002 → Jul 2006	osteoporosis	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT01812551 Comparator	Oct 2002 → Jul 2006	cystic fibrosis, osteoporosis	Istituto Auxologico Italiano	Completed	No outcome recorded
Phase 3	NCT00000412 Comparator	Sep 1997 → Apr 2002	osteoporosis	Columbia University	Completed	No outcome recorded
Phase 4	NCT06856369 Comparator	Jan 2025 → Feb 2026 overdue	chronic periodontitis	Bahria University	Active not recruiting	No outcome recorded
Phase 4	NCT05645289 Comparator	Jan → Dec 2023	postmenopausal osteoporosis	Peking University Third Hospital	Unknown	No outcome recorded
Phase 4	NCT05493761 Comparator	Dec 2022 → Jul 2026 overdue	NAFLD1, postmenopausal osteoporosis	Aristotle University Of Thessaloniki	Active not recruiting	No outcome recorded
Phase 4	NCT05151484 Comparator	Mar 2022 → Jan 2027 expected	osteoporosis	Madhumathi Rao	Active not recruiting	No outcome recorded
Phase 4	NCT04177940 Comparator	Aug 2020 → Jul 2024	osteoporosis	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 4	NCT03623633 Comparator	Nov 2018 → Feb 2023 overdue	postmenopausal osteoporosis	Massachusetts General Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT03005678 Comparator	Apr 2017 → Nov 2019	osteoporosis	Tuen Mun Hospital	Completed	No outcome recorded
Phase 4	NCT03006003 Comparator	Jan 2017 → Dec 2021	depressive disorder	Taichung Veterans General Hospital	Unknown	No outcome recorded
Phase 4	NCT02322099 Comparator	May 2016 → Sep 2019	disease of bone structure	University College Dublin	Terminated	No outcome recorded
Phase 4	NCT02139007 Comparator	Jun 2014 → Jun 2016	osteoporosis	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 4	NCT02371252 Comparator	Apr 2014 → Dec 2016	osteoporosis	Mahidol University	Completed	No outcome recorded
Phase 4	NCT01750086 Comparator	Jan 2013 → Apr 2014	postmenopausal osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT01770106 Comparator	Dec 2012 → Jun 2014	rheumatoid arthritis	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 4	NCT00713258 Comparator	Apr 2008 → May 2010	—	Nycomed	Terminated	No outcome recorded
Phase 4	NCT00729651 Comparator	Mar 2008 → Apr 2009	postmenopausal osteoporosis	Organon and Co	Completed	Met primary
Phase 4	NCT00503113 Comparator	Jul 2007 → Apr 2010	postmenopausal osteoporosis	Hoffmann-La Roche	Completed	No outcome recorded
Phase 4	NCT00395382 Comparator	Jan 2007 → Sep 2009	arteriosclerosis disorder, calcinosis	Monash University	Completed	No outcome recorded
Phase 4	NCT00359385 Comparator	Jul 2006 → Sep 2009	primary hyperparathyroidism	Columbia University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT00460057 Comparator	Mar → Dec 2006	osteoporosis	Eulji University Hospital	Completed	No outcome recorded
Phase 4	NCT01535027 Comparator	Mar 2006 → Dec 2012	osteoporosis	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT00504166 Comparator	Feb 2006 → Mar 2009	osteoporosis	University of California, San Francisco	Completed	No outcome recorded
Phase 4	NCT00727493 Comparator	Jan 2004 → Jan 2010	osteoporosis	Charite University, Berlin, Germany	Unknown	No outcome recorded
Phase 4	NCT00157690 Comparator	Dec 2003 → Aug 2006	cystic fibrosis, osteoporosis	McMaster University	Completed	No outcome recorded
Phase 4	NCT02416271 Comparator	Apr 2001 → May 2003	osteoporosis	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00159419 Comparator	Aug 1999 → Aug 2008	bone Paget disease, osteogenesis imperfecta, osteoporosis	Indiana University	Completed	No outcome recorded
—	NCT07242612 Comparator	Oct 2025 → Mar 2026 overdue	postmenopausal osteoporosis	Khyber Medical University Peshawar	Recruiting	No outcome recorded
—	NCT04555317 Background	May 2021 → Aug 2025	female reproductive organ cancer	The Christie NHS Foundation Trust	Unknown	No outcome recorded
—	NCT05662358 Comparator	Jan 2021 → Sep 2023	drug pseudoallergy	Shenzhen People's Hospital	Unknown	No outcome recorded
—	NCT02304757 Comparator	Jan 2015 → Dec 2019	differentiated thyroid carcinoma, osteoporosis	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
—	NCT01656629 Comparator	Aug 2012 → Jun 2014	osteoporosis	Johns Hopkins University	Terminated	No outcome recorded Stop: Business
—	NCT01131884 Comparator	Jun 2010 → Dec 2012	osteoporosis, spinal cord injury	University of Rochester	Terminated	No outcome recorded Stop: Enrollment
—	NCT01020253 Comparator	Jan 2006 → Apr 2008	bone disorder	Yokohama City University Medical Center	Unknown	No outcome recorded
—	NCT00580047 Comparator	Dec 2003 → Jul 2014	impaired renal function disease	University of Nebraska	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 9

Date	Issuer	Release
2023-05-08	Amgen	Results NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE amgen.com ↗ Treatment with Prolia was also associated with greater reductions in fracture risk over time.
2021-02-15	EffRx Pharmaceuticals SA	Results EffRx Pharmaceuticals Announces the Release of Binosto® Data in Two Publications effrx.com ↗ FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced the publication of new scientific data on its Binosto ® (buffered soluble alendronate).
2017-09-11	Amgen	Results EVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine amgen.com ↗ The results were simultaneously published in the New England Journal of Medicine (NEJM) and presented today as a late-breaking abstract at an oral scientific session at the Annual Meeting of the American Society for Bone Mineral Research (ASBMR) in Denver.
2017-06-15	Yuyu Pharma, Inc.	Results 유유제약, 골다공증 치료제 맥스마빌정 임상4상 골절예방효과 입증 yuyu.co.kr ↗ 위 환자를 대상으로 맥스마빌정 투여 후 12개월 추적 관찰한 결과, 골다공증성 골절 발생율은 약 2.7%였고, 요추 골밀도 및 고관절 골밀도는 각각 5% 및 1.5% 개선되었다.
2008-09-12	Sun Pharmaceutical Industries, Inc.	Regulatory Sun Pharma gets USFDA approval for generic Fosamax® tablets sunpharma.com ↗ Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted final approval for the Company’s Abbreviated New Drug Application (ANDA) for generic Fosamax ®, alendronate sodium tablets.
2008-02-06	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Approval of Generic Fosamax® Tablets tevapharm.com ↗ the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Merck's osteoporosis treatment Fosamax® (Alendronate Sodium) Tablets, 5 mg, 10 mg, 35 mg, 40 mg and 70 mg.
2007-11-14	Eli Lilly and Company	Results FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis lilly.com ↗ In this head-to-head comparator study, the increase in lumbar spine BMD was significantly greater in patients receiving teriparatide compared with alendronate at 6, 12, and 18 months of treatment (p 0.001 at all time points).
2005-08-08	Eli Lilly and Company	Results New Study Provides In-Depth Look at How Osteoporosis Treatments Function Within Bone lilly.com ↗ The study, which provides more in-depth information than previously available about these two treatments, found that both therapies increase bone mineral density (BMD), but to different degrees and through different means.
2002-12-30	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Tentative Approval of Alendronate Sodium Tablets tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has granted tentative approval for the company's ANDA for Alendronate Sodium Tablets, 5 mg, 10 mg, 35 mg, 40 mg and 70 mg.

All press releases naming this drug 38 releases

Date	Issuer	Release
2024-02-16	Lupin Limited	EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Lupin for Commercialization of BINOSTO® in Vietnam & Philippines lupin.com ↗
2023-09-19	Radius Health, Inc.	Radius Health Announces Expansion of its Bone Health Business Through the Exclusive Licensing of U.S. Rights to BINOSTO® for Osteoporosis radiuspharm.com ↗
2023-05-08	Amgen	NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE amgen.com ↗
2021-02-15	EffRx Pharmaceuticals SA	EffRx Pharmaceuticals Announces the Release of Binosto® Data in Two Publications effrx.com ↗
2017-09-11	Amgen	EVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine amgen.com ↗
2017-06-15	Yuyu Pharma, Inc.	유유제약, 골다공증 치료제 맥스마빌정 임상4상 골절예방효과 입증 yuyu.co.kr ↗
2013-12-09	Merck Sharp & Dohme LLC	Merck Favorably Resolves FOSAMAX® (alendronate sodium) ONJ litigation merck.com ↗
2013-06-27	Merck Sharp & Dohme LLC	Federal MDL Court Rules Plaintiff’s Failure to Warn Claim Pre-empted in FOSAMAX® (alendronate sodium) Bellwether Case merck.com ↗
2013-04-29	Merck Sharp & Dohme LLC	Merck Wins FOSAMAX® (alendronate sodium) Federal Bellwether Trial Involving Atypical Femur Fracture Claims merck.com ↗
2013-04-09	Merck Sharp & Dohme LLC	Statement on FOSAMAX® (alendronate sodium) Product Liability Trial merck.com ↗
2013-03-18	Merck Sharp & Dohme LLC	Mistrial Declared in FOSAMAX® (alendronate sodium) New Jersey State Court Trial merck.com ↗
2013-03-11	Merck Sharp & Dohme LLC	Statement on FOSAMAX® (alendronate sodium) Product Liability Trial merck.com ↗
2013-03-11	Merck Sharp & Dohme LLC	Statement on FOSAMAX® (alendronate sodium) Product Liability Trial merck.com ↗
2013-02-05	Merck Sharp & Dohme LLC	Mixed Result in Federal Trial Involving FOSAMAX® (alendronate sodium) merck.com ↗
2013-01-14	Merck Sharp & Dohme LLC	Statement on FOSAMAX® (alendronate sodium) Product Liability Trial merck.com ↗
2012-04-18	Merck Sharp & Dohme LLC	Merck Wins Another FOSAMAX® (alendronate sodium) State Court Trial merck.com ↗
2012-02-27	Merck Sharp & Dohme LLC	Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in New Jersey merck.com ↗
2011-10-03	Merck Sharp & Dohme LLC	Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX® (alendronate sodium) merck.com ↗
2011-09-07	Merck Sharp & Dohme LLC	Statement on FOSAMAX® (alendronate sodium) Product Liability Trial merck.com ↗
2011-02-14	Merck Sharp & Dohme LLC	Merck Wins First FOSAMAX® (alendronate sodium) State Court Trial merck.com ↗
2011-01-18	Merck Sharp & Dohme LLC	Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in New Jersey State Court merck.com ↗
2010-11-19	Merck Sharp & Dohme LLC	Merck Wins Another Federal FOSAMAX® (alendronate sodium) Bellwether Trial merck.com ↗
2010-10-28	Merck Sharp & Dohme LLC	Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court merck.com ↗
2010-10-04	Merck Sharp & Dohme LLC	Merck to Appeal Reduced Jury Verdict in Federal FOSAMAX® (alendronate sodium) Case merck.com ↗
2008-09-12	Sun Pharmaceutical Industries, Inc.	Sun Pharma gets USFDA approval for generic Fosamax® tablets sunpharma.com ↗
2008-04-11	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Brussels Court Decision To Revoke MSD's European Patent On Fosamax® tevapharm.com ↗
2008-02-25	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Two Court Decisions to Revoke MSD's European Patent on Generic Fosamax® tevapharm.com ↗
2008-02-06	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval of Generic Fosamax® Tablets tevapharm.com ↗
2007-11-14	Eli Lilly and Company	FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis lilly.com ↗
2005-08-08	Eli Lilly and Company	New Study Provides In-Depth Look at How Osteoporosis Treatments Function Within Bone lilly.com ↗
2005-01-28	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Court Of Appeals Grants Favorable Ruling On Once-A-Week Version Of Fosamax® tevapharm.com ↗
2003-11-06	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces English Court Of Appeal Upholds Lower Court Ruling To Revoke Two Fosamax® Patents tevapharm.com ↗
2003-10-30	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Court Of Appeals Upholds Lower Court Ruling On Daily Version Of Fosamax® tevapharm.com ↗
2003-08-29	Teva Branded Pharmaceutical Products R&D, Inc.	Teva to Appeal Lower Court Ruling on Weekly Version of FOSAMAX® tevapharm.com ↗
2003-01-21	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces U.K. High Court Revokes Two Fosamax ® Patents tevapharm.com ↗
2002-12-30	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Tentative Approval of Alendronate Sodium Tablets tevapharm.com ↗
2002-11-05	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Intends to Appeal Court Ruling on Fosamax® tevapharm.com ↗
2001-07-25	Eli Lilly and Company	Head-to-Head Osteoporosis Fracture Study to Compare Evista® and Fosamax® lilly.com ↗

Evidence & citations 33 cited values

Every value below carries the sentence it was read from. 166 sources stand behind the page.

Field	Value	Cited text
Known as	Alendronic Acid	“Topical Alendronic Acid on Alveolar Bone Remodeling After Tooth Extraction” NCT05602493 ↗ 1 NCT02132026 ↗
Known as	Acide alendronique	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	Acido alendronico	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	Adrovance	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	alendronate	“The purpose of this study is to evaluate the use of an oral bisphosphonate (alendronate) in preventing bone loss in postmenopausal women with early breast cancer who are...” NCT00122356 ↗ 148 “This randomized, open-label study compared the effects of once weekly alendronate 70 mg containing 5600 IU vit-D₃ (ALN/D5600) to alendronate 70 mg without additional vit-D...” PMID 24719139 ↗ Apr 2014 “Postmenopausal women with osteoporosis on alendronate or raloxifene for at least 18 months added teriparatide (Add groups) or switched to teriparatide (Switch groups) for 18 months.” PMID 19584192 ↗ Jul 2009 “Participants received alendronate 70 mg once weekly (ALN OW) or placebo; all received supplemental daily calcium (1000 mg) and 400 IU vitamin D.” PMID 19487264 ↗ Jun 2009 “Switch from Denosumab 60 mg administered subcutaneously (SC) to weekly oral alendronate (70 mg; started 6 months after last denosumab dose)” NCT04177940 ↗ “A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)” NCT00389740 ↗ “Alendronate Sodium trihydrate, m.w 325.12, Pharmaceutical Secondary standard, PHR 1599” NCT04140006 ↗ “This study compared liquid and tablet forms of alendronate for osteoporosis treatment.” PMID 39589664 ↗ Nov 2024 “1. Bisphosphonates: fasting oral alendronate 70mg/w for 24 weeks.” NCT07435051 ↗ “Alendronate 70mg once weekly / 24 mos” NCT00532337 ↗ “Alendronate 5mg + calcitriol 0.5 μg” NCT01526278 ↗ Show 138 more sources
Known as	Alendronate (as sodium)	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	alendronate sodium	“We will enroll patients who have undergone cardiac transplantation into a randomized, double-blind, 12-month study of the efficacy and safety of calcitriol (Rocaltrol) and...” NCT00000412 ↗ 19 “an Oral Buffered Solution of Alendronate Sodium 70 mg Once-Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women” NCT00092027 ↗ “70 mg alendronate sodium tablet weekly and a minodronate tablet matching placebo monthly for 48 weeks.” NCT05305183 ↗ “MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks” NCT00092079 ↗ “One bisphosphonate, namely alendronate sodium (or alendronate) is chosen” NCT01770106 ↗ “MK0217, alendronate sodium / Duration of Treatment : 2 Years” NCT00398606 ↗ “MK0217, alendronate sodium / Duration of Treatment : 5 Years” NCT00398931 ↗ “MK0217, alendronate sodium / Duration of Treatment: 1 Month” NCT00400530 ↗ “MK0217, alendronate sodium/Duration of Intervention: 12 mo” NCT00092040 ↗ “Alendronate Sodium Tablets, 70 mg” NCT01012934 ↗ “Alendronate Sodium Tablets, 10 mg” NCT00983996 ↗ Show 9 more sources
Known as	Alendronate sodium component of fosamax plus d	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	Alendronate sodium hydrate	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00680953 ↗
Known as	Alendronate Sodium Tablets	“Minodronate Tablets and Alendronate Sodium Tablets-matching placebo;Alendronate Sodium Tablets and Minodronate Tablets -matching placebo” NCT05305183 ↗
Known as	Alendronate sodium trihydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	Alendronic acid monosodium salt trihydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	ALN	“This randomized, open-label study compared the effects of once weekly alendronate 70 mg containing 5600 IU vit-D₃ (ALN/D5600) to alendronate 70 mg without additional vit-D...” PMID 24719139 ↗ Apr 2014 10 “In the Fracture Intervention Trial (FIT) Long Term Extension (FLEX) Trial, 10 years of alendronate (ALN) did not significantly reduce the risk of nonvertebral fractures (NVFs)...” PMID 20200926 ↗ May 2010 “METHODS: This randomized, active and placebo-controlled, dose-ranging study enrolled 526 postmenopausal women, who had taken alendronate (ALN) for ≥12 months preceding the...” PMID 26556736 ↗ Nov 2015 “During a 2-year extension, women in the daily TPTD group were switched to alendronate (ALN) and those in the cyclic TPTD group continued on cyclic TPTD (without any ALN).” PMID 36410666 ↗ Nov 2022 “Alendronate (ALN) After SRP, ALN gel was delivered subgingivally into the pocket” NCT02461667 ↗ “Locally delivered Alendronate (ALN) have potent inhibitory effect on bone” NCT02168543 ↗ “Denosumab (DMAB) to Alendronate (ALN)” NCT04177940 ↗ “with drugs like alendronate (ALN).” NCT01656629 ↗ “Alendronate Gel (ALN)” NCT04140006 ↗ “Alendronate (ALN)” NCT05527548 ↗ “alendronate (ALN)” NCT07216794 ↗
Known as	ALN OW	“Participants received alendronate 70 mg once weekly (ALN OW) or placebo; all received supplemental daily calcium (1000 mg) and 400 IU vitamin D.” PMID 19487264 ↗ Jun 2009
Known as	ALN-S	“once-weekly low-volume liquid alendronate sodium trihydrate (ALN-S), an oral solution, to once-weekly alendronate sodium (ALN-T), an oral tablet” PMID 39589664 ↗ Nov 2024
Known as	ALN-T	“once-weekly low-volume liquid alendronate sodium trihydrate (ALN-S), an oral solution, to once-weekly alendronate sodium (ALN-T), an oral tablet” PMID 39589664 ↗ Nov 2024
Known as	Binosto	“Binosto (effervescent and buffered alendronate)” NCT05325515 ↗
Known as	Fosamax	“The overall goal of this proposal is to determine the effectiveness and safety of once weekly alendronate (Fosamax) in the prevention and treatment of osteoporosis in men with...” NCT00177619 ↗ 18 “We will enroll patients who have undergone cardiac transplantation into a randomized, double-blind, 12-month study of the efficacy and safety of calcitriol (Rocaltrol) and...” NCT00000412 ↗ “To compare upper GI handling of fosamax and generic, because the main AE profile of alendronate is before systemic absorption in the esophagus; differences could be relevant to...” NCT00400530 ↗ “The potent bisphosphonate, alendronate (Fosamax), reduces bone remodeling and enhances secondary mineralization.” NCT00359385 ↗ “treatment of glucocorticoid-associated osteopenia and osteoporosis with 18 months of alendronate (FOSAMAX®)” NCT00209469 ↗ “Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp \& Dohme．LTD.).” NCT02303873 ↗ “Alendronate (Fosamax) is a drug that works by stopping bone resorption (break down).” NCT00001720 ↗ “Fosamax (aledronate sodium 70mg, oral tablet)” NCT05387200 ↗ “Comparator: Alendronate sodium (Fosamax)” NCT00729651 ↗ “Alendronate (Fosamax) 70mg every week.” NCT01460654 ↗ “Fosamax (conventional alendronate)” NCT05325515 ↗ Show 8 more sources
Known as	Fosavance	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	G-704,650	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	Masibone S	“Masibone S (alendronate sodium trihydrate 70mg, oral solution)” NCT05387200 ↗
Known as	MK-217	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	MK0217	“MK0217, alendronate sodium / Duration of Treatment : 2 Years” NCT00398606 ↗ 3 “MK0217, alendronate sodium / Duration of Treatment : 5 Years” NCT00398931 ↗ “MK0217, alendronate sodium / Duration of Treatment: 1 Month” NCT00400530 ↗ “MK0217, alendronate sodium/Duration of Intervention: 12 mo” NCT00092040 ↗
Known as	NSC-722597	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	NSC-758931	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	Sedron	“Sedron (alendronate) 70 mg taken orally once a week for 12 months” NCT01889134 ↗
Known as	Sodium alendronate	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02470611 ↗
Known as	Sodium alendronate trihydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Known as	Vantavo	ChEMBL registry synonym — accepted as the source's own label CHEMBL870 ↗
Action	Inhibit	“Alendronate is a drug that blocks or reduces bone loss” NCT00000427 ↗ 1 “Farnesyl diphosphate synthase inhibitor” CHEMBL870 ↗
Modality	Small molecule	“a bisphosphonate, alendronate (ALN)” NCT00000430 ↗
Route	Oral	“70 mg/week by oral route” NCT00000400 ↗
Target	FDPS	“Farnesyl diphosphate synthase inhibitor” CHEMBL870 ↗